Your browser doesn't support javascript.
loading
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Loibl, S; Majewski, I; Guarneri, V; Nekljudova, V; Holmes, E; Bria, E; Denkert, C; Schem, C; Sotiriou, C; Loi, S; Untch, M; Conte, P; Bernards, R; Piccart, M; von Minckwitz, G; Baselga, J.
Afiliação
  • Loibl S; German Breast Group, Neu-Isenburg, Germany sibylle.loibl@gbg.de.
  • Majewski I; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padua, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Nekljudova V; German Breast Group, Neu-Isenburg, Germany.
  • Holmes E; Frontier Science Scotland, Kincraig, UK.
  • Bria E; Department of Medical Oncology, University of Verona, Verona, Italy.
  • Denkert C; Institute of Pathology, Charité Universitätsmedizin Berlin, and German Cancer Consortium (DKTK), Berlin.
  • Schem C; Department of Obstetrics and Gynecology, University Hospital Kiel, Kiel, Germany.
  • Sotiriou C; Institut Jules Bordet, Université Libre de Bruxelles, Brussel, Belgium.
  • Loi S; Peter MacCallum Cancer Centre, East Melbourne, Australia.
  • Untch M; Department of Obstetrics and Gynecology, Helios-Klinikum, Berlin-Buch, Germany.
  • Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padua, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Bernards R; The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Piccart M; Institut Jules Bordet, Université Libre de Bruxelles, Brussel, Belgium.
  • von Minckwitz G; German Breast Group, Neu-Isenburg, Germany.
  • Baselga J; Memorial Sloan-Kettering Cancer Center, New York, USA.
Ann Oncol ; 27(8): 1519-25, 2016 08.
Article em En | MEDLINE | ID: mdl-27177864
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinazolinas / Neoplasias da Mama / Receptor ErbB-2 / Classe I de Fosfatidilinositol 3-Quinases / Trastuzumab Tipo de estudo: Risk_factors_studies / Systematic_reviews Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Quinazolinas / Neoplasias da Mama / Receptor ErbB-2 / Classe I de Fosfatidilinositol 3-Quinases / Trastuzumab Tipo de estudo: Risk_factors_studies / Systematic_reviews Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article